Cascadian Therapeutics Inc. (NASDAQ:CASC)‘s stock had its “buy” rating reaffirmed by research analysts at Cowen and Company in a research report issued on Monday.

A number of other brokerages have also recently commented on CASC. Zacks Investment Research raised Cascadian Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a report on Tuesday, October 4th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $2.00 target price on shares of Cascadian Therapeutics in a report on Wednesday, June 15th. Finally, Jefferies Group reaffirmed a “buy” rating on shares of Cascadian Therapeutics in a report on Wednesday, June 15th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Cascadian Therapeutics has an average rating of “Buy” and an average target price of $3.20.

Shares of Cascadian Therapeutics (NASDAQ:CASC) traded down 2.349% during midday trading on Monday, reaching $1.455. The company’s stock had a trading volume of 724,662 shares. The company’s 50-day moving average price is $1.32 and its 200-day moving average price is $1.17. The company’s market cap is $196.88 million. Cascadian Therapeutics has a 12 month low of $0.82 and a 12 month high of $3.75.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Cascadian Therapeutics (NASDAQ:CASC) last announced its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by $0.14. During the same period in the prior year, the company earned ($0.11) earnings per share. On average, equities analysts anticipate that Cascadian Therapeutics will post $5.02 EPS for the current fiscal year.

In other Cascadian Therapeutics news, insider Scott Dunseth Myers purchased 45,000 shares of the business’s stock in a transaction on Wednesday, August 17th. The stock was acquired at an average price of $1.15 per share, for a total transaction of $51,750.00. Following the purchase, the insider now owns 107,500 shares of the company’s stock, valued at approximately $123,625. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 19.40% of the stock is owned by company insiders.

Cascadian Therapeutics Company Profile

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

5 Day Chart for NASDAQ:CASC

Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with's FREE daily email newsletter.